Navigation Links
Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Date:10/5/2007

FRANKLIN, Mass., Oct. 5 /PRNewswire-FirstCall/ -- Following its recent merger with Echo Therapeutics, Inc., Sontra Medical Corporation (OTC Bulletin Board: SONT), a dual platform-enabled transdermal specialty therapeutics and diagnostics company, today announced that it has changed its corporate name to Echo Therapeutics, Inc., effective Monday, October 8, 2007. In addition, on October 8, 2007, the Company's OTC Bulletin Board ticker symbol will change to "ECTE" and its corporate website address will become http://www.echotx.com.

"Our new name better reflects our expanded strategic focus on building a broad pipeline of advanced topical formulations of FDA-approved specialty pharmaceutical products and next generation needle-free transdermal diagnostics," said Patrick T. Mooney, M.D., CEO of Echo Therapeutics.

About Echo Therapeutics

Echo Therapeutics is a dual platform-enabled, specialty therapeutics and diagnostics company developing an extensive pipeline of advanced topical formulations of FDA-approved products and a suite of needle-free transdermal diagnostics. Echo is developing a next generation, needle-free Continuous Transdermal Glucose Monitor (CTGM) system for use in the diabetes home care and hospital critical care markets. Echo's next generation CTGM system leverages its FDA-approved SonoPrep(R) ultrasound-mediated skin permeation technology platform. Echo is also developing a broad portfolio of advanced topical formulations of well-established, FDA-approved products using its proprietary AzoneTS(TM) dermal penetration technology. Echo has submitted a New Drug Application (NDA) to the FDA for the approval of its lead Azone TS- based product, Durhalieve(TM), for the treatment of corticosteroid responsive dermatoses.

SonoPrep is a registered trademark of Echo Therapeutics, Inc.

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward- looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to our ability to develop, market and sell pharmaceutical or diagnostic products based on our AzoneTS and SonoPrep platform technologies, including AzoneTS-based Durhalieve for corticosteroid responsive dermatoses and a SonoPrep-based continuous transdermal glucose monitor system for the diabetes and hospital critical care markets; the availability of substantial additional equity capital to support our robust research, development and product commercialization activities; and the success of our AzoneTS and SonoPrep business, research, development, and regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-KSB for the year ended December 31, 2006, our most recent quarterly reports on Form 10-QSB, and our current reports on Form 8-K. Echo Therapeutics, Inc. does not undertake to update these forward-looking statements.

10 Forge Parkway

Franklin, MA 02038, USA

Tel: 1+ 877-4-SONTRA (766878)

Fax: 1+ 508-553-8760

http://www.echotx.com

Investor Relations Contacts:

Patrick T. Mooney, M.D., CEO

508-530-0329

pmooney@echotx.com


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Check if your “Favourite medical web-site” is indulging in Quackey
2. Teens turning to Internet for medical queries
3. Robots craft medical history
4. NBE to conduct test for medical students from abroad
5. Air pollution combined with greater medical needs
6. Indian Nationals with Foreign Medical Degrees can now practice in India
7. Children! Protecting them from medical mistakes
8. More information sought by patients on medical errors
9. SARS necessitates medical masks
10. Meditation Works Medically
11. Sleep Disorders Could Indicate Other Medical Problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, ... relay – Miles by Moonlight to raise money for the American Heart Association Heart ... , Teams will work together to keep their treadmills moving for 5 hours. ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... ... presenting the latest in wound care advancements to physician colleagues, skilled nursing facility ... is titled, "Navigating the Treacherous Waters of Wound Care." , "At many of ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and ... financial results for the third quarter of 2017 on ... conference call on that day with the investment community ... The conference call will begin at 9 ... can access a live webcast of the conference call ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the European ... system called the HORIZON at MIBio 2017 in Cambridge, ... and visible particulate matter in biopharmaceutical samples with unprecedented speed and ... the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
Breaking Medicine Technology: